Mayne Pharma closes on $652M cash generics deal with Teva and Allergan

​Mayne Pharma has closed its $652 million all-cash deal to acquire a portfolio of 42 drug products in what is believed to be the largest generic drug divestiture overseen by the Federal Trade Commission.